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OBJECTIVE — To determine the relationship between subclinical hypothyroidism (SCH)
and the prevalence of diabetic retinopathy in type 2 diabetic patients.
RESEARCHDESIGNANDMETHODS — Atotalof1,170type2diabeticpatientswere
screened for thyroid function. There were 127 type 2 diabetic patients with SCH and 200
randomly selected euthyroid type 2 diabetic patients selected. Those with more severe than
moderate nonproliferative diabetic retinopathy were classiﬁed as having sight-threatening dia-
betic retinopathy (STDR).
RESULTS — The trend for severe retinopathy was signiﬁcantly higher in the SCH group than
in the euthyroid group (
2  20.43, P  0.000). SCH was associated with greater prevalence of
diabetic retinopathy, especially STDR [odds ratio (95% CI): 4.15 (2.17–7.96), P  0.000] after
an adjustment for age, sex, duration of diabetes, A1C, BMI, hypertension, and LDL cholesterol.
Eveneuthyroidpatientswiththyroid-stimulatinghormonelevelsbetween2.0and4.0IU/ml
had a higher rate of STDR then those between 0.4 and 2.0 IU/ml (P  0.008).
CONCLUSIONS — Type 2 diabetic patients with SCH are associated with an increased risk
of STDR.
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D
iabetic retinopathy is one of the
most common microvascular com-
plications and the leading cause of
blindness worldwide. Common risk fac-
torsforthedevelopmentofmicrovascular
complications include duration of diabe-
tes,poorglycemiccontrol,elevatedblood
pressure, and dyslipidemia (1,2).
Subclinical hypothyroidism (SCH) is
deﬁned as an asymptomatic state charac-
terized by a normal serum thyroxin level
and elevated serum concentration of thy-
rotropin (thyroid-stimulating hormone
[TSH]). Patients with SCH sustain an ob-
vious increase in cardiovascular event
rates (3,4). Despite this, there is a distinct
lack of relevant research into risk factors
associated with microvascular complica-
tions in type 2 diabetes with SCH. In fact,
only a single study conducted by Chen et
al. (5) has attempted to elucidate these
issues. Yet this study focused predomi-
nantly on the issue of diabetic nephropa-
thy, as deﬁned solely by elevated
microalbuminuria, rather than retinopa-
thy. However, in most diabetic patients
with elevated microalbuminuria, other
chronic kidney diseases should be con-
sideredintheabsenceofdiabeticretinop-
athy (6). Our investigation examined the
relationship between SCH and diabetic
retinopathy in large Chinese type 2 dia-
betic patient samples.
RESEARCH DESIGN AND
METHODS— A total of 1,170 sub-
jects comprising hospital-based patients
with type 2 diabetes (aged 59.3  14.0
years, with a mean duration of known
diabetes for 8.8  6.8 years) were
investigated. Those with normal free tri-
iodothyronine (FT3), free thyroxine
(FT4), and an increased TSH (4 IU/
ml) level were diagnosed with SCH. We
further divided euthyroid type 2 diabetic
patients into two subgroups (TSH: 2.0 to
4.0 vs. 0.4 to 2.0 IU/ml) and com-
pared the two based on a more stringent
“normal” reference interval of TSH sug-
gested by the National Health and Nutri-
tion Examination Survey (NHANES) III
(7). All type 2 diabetic patients with SCH
and200casesofeuthyroidtype2diabetic
patients randomly selected from the
1,170 subjects were included in the fur-
ther investigation. Digital retinal photo-
graphs (two eyes  two ﬁelds), taken
using a TRC-NW7SF (Topcon, Tokyo,
Japan)non-mydriaticcameraat45°,were
examinedindependentlybytwoqualiﬁed
retinal photography graders following
quality assurance protocols. The severity
of diabetic retinopathy was graded based
on the international clinical diabetic reti-
nopathyseverityscale(8).Eyeswithmore
severe than moderate nonproliferative di-
abetic retinopathy were classiﬁed as
sight-threatening diabetic retinopathy
(STDR). Others were considered as hav-
ing non–sight-threatening diabetic reti-
nopathy(NSTDR).Datawereanalyzedby
an unpaired Student t test, Mann-
Whitney U test, Fisher exact test, 
2 test,
and multiple logistic regression.
RESULTS— A total of 127 (10.9%)
type 2 diabetic patients had SCH. No sig-
niﬁcant differences between the SCH and
euthyroid groups in age, duration of
knowndiabetes,BMI,systolicbloodpres-
sure, or biochemical parameters were
found, except diastolic blood pressure,
LDLcholesterol,andglomerularﬁltration
rate (GFR). The trend to severe retinopa-
thy in the SCH group was signiﬁcantly
higher than in the non-SCH group (
2 
20.43, P  0.000) (Table 1).
After an adjustment for potential ex-
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with diabetic retinopathy [odds ratio
(95% CI): 2.02 (1.18–3.46), P  0.011]
andSTDR[4.15(2.17–7.96),P0.000].
Additionally,type2diabeticpatientswith
SCH had a signiﬁcantly lower glomerular
ﬁltration rate.
In 200 euthyroid type 2 diabetic pa-
tients, 187 patients without cataracts
were analyzed. Of the 187 patients, 15 of
125patients(12.0%)withaTSHlevelbe-
tween 0.4 and 2.0 mU/l had STDR, while
13 of 34 patients (38.2%) with a TSH
level between 2.0 and 4.0 IU/ml had
STDR. A subgroup with a higher TSH
level had a signiﬁcantly higher rate of
STDR (Fisher exact test, P  0.008).
CONCLUSIONS — SCH is a com-
mon endocrine disorder and has been
reportedtorangefrom4to10%inlarge
general population screening surveys
(9) and has been found to be 4–17% in
diabetic patients in previous studies
(10).
SCH is an asymptomatic stage of hy-
pothyroidism, but it is often complicated
with endothelial dysfunction, including
capillaryandprecapillaryarterioles,man-
ifestedbythickeningofthecapillarybase-
ment membrane (11). Serum high-
sensitive C-reactive protein levels in
subjects with SCH were higher than con-
trol subjects (12). These changes lead to
small vessel dysfunction (13), increasing
the prevalence of retinopathy. The refer-
ence range for “normal” TSH has been the
focus of considerable debate. Some clini-
cians have advocated reducing the upper
limit of the normal reference interval for
TSH to 2.5 or 3.0 mIU/l. Individuals in
the 3.0–5.0 mIU/l TSH range are consid-
ered as possibly exhibiting the early signs
of developing hypothyroidism, prompt-
ing continued monitoring (14). Our
study supports this, since euthyroid pa-
tients with TSH levels between 2.0 and
4.0 IU/ml demonstrated a higher rate
ofSTDRthanpatientswithlevelsbetween
0.4 and 2.0 IU/ml.
Concerninglimitations,thisstudyisa
cross-sectional study and cannot offer an
explanation as to why type 2 diabetic pa-
tients with SCH had a high level of C-
peptide and “better” glucose control, a
ﬁnding which may warrant further
investigation.
Routine screening for thyroid func-
tion in the general population and thy-
roxin replacement in patients with TSH
within 4–10 IU/ml is still controversial
(15). Our ﬁndings suggest that type 2 di-
abetic patients with SCH demonstrated a
higher prevalence of retinopathy than
their non-SCH counterparts. A random-
izedcontrolledtrialmayprovideevidence
to support screening of thyroid function
and the potential treatment of SCH in
type 2 diabetic patients.
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Severe NPDR 12 (6.0) 22 (17.3)
Mild and moderate NPDR 59 (29.5) 28 (22.0)
Normal 100 (50.0) 44 (34.6)
Unknown 13 (6.5) 12 (9.4)
Data are means  SD or median (range) unless otherwise indicated. MNPDR, mild and moderate NPDR;
NPDR, nonproliferative diabetic retinopathy; SNPDR, severe NPDR. Unknown, withcataracts or could not
check the ocular fundus. Student t test;*Mann-Whitney U test; †Fisher exact test; ‡Pearson 
2 test, 
2 
20.43. Data in bold are statistically signiﬁcant.
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